Akeega + AAP Halves Progression Risk in HRR-mutated mCSPC – AMPLITUDE Trial

Published

July 26, 2025

Author

Lansbury Sinclair

Lansbury is an intelligence analyst focused on immunology. She tracks clinical and market developments across psoriasis, psoriatic arthritis, and lupus.

Johnson & Johnson announced interim AMPLITUDE trial results on June 3, 2025. The combination of niraparib + abiraterone acetate + prednisone (Akeega + AAP) reduced radiographic progression or symptom progression by ~50% versus AAP alone in HRR-mutated metastatic castration-sensitive prostate cancer (mCSPC). The benefit was most pronounced in BRCA-positive patients. This marks the first PARP + ARPI combination to demonstrate statistically significant benefit in this setting.

‍Citation: https://www.jnj.com/media-center/press-releases/johnson-johnson-leads-with-first-parp-inhibitor-combo-to-improve-efficacy-in-patients-with-hrr-altered-mcspc

‍Implication: Akeega is now positioned to enter earlier prostate cancer treatment lines. Competitive response from Lynparza and Talzenna + Xtandi should be anticipated.